VivoSeq
Other

Angiomyolipoma

3

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Angiomyolipoma is an early-stage landscape with 3 programs across 1 company. The most active players are Novartis.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

50/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

3 programs

Phase 2

Pipeline

Programs by Phase

Preclinical1

Votubia

Novartis

Phase 1
No programs
Phase 22

Everolimus

Novartis

RAD001

Novartis

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

2

clinical trials

Terminated1 · 50%
Completed1 · 50%

Clinical Trials

Trial Activity

Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus
Terminated·FFox Chase Cancer Center·Phase 2·NCT02539459·20 enrolled
RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM
Completed·—·Phase 1/2·NCT00457964·36 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)